The Contractor shall synthesize, purify, characterize, and submit to the Drug Synthesis and Chemistry Branch (DSCB) target compounds of high purities, as specified by the Contracting Officer Representative (COR), and small libraries of analogs of lead compounds as needed. Tasks may include synthesis, purity evaluation, or determination of physicochemical properties as specified on individual task orders. The NCI expects that 1 to 25 compounds, both synthetics and natural products, will be synthesized each year during the five (5) year award period. Contractor must have a demonstrated ability, in the recent past, to carry out multi-step synthesis to routinely deliver up to 1,000 grams of the target compound and, on occasion, deliver up to 5,000 grams of the target compound.
Many stories of successful cancer research follow a familiar arc: one of curiosity, iteration, collaboration, and persistence. The development of endoxifen, an investigational drug for breast cancer, is no different.
Like many research advances, the endoxifen story started with intriguing basic research findings that the research community continuously expanded on, eventually leading to clinical trials.
But this progress, and that of many other cancer research projects, was dependent on a critical component: endoxifen’s development would not have been possible without the support of NCI, as well as other government, nonprofit, and philanthropic organizations.